1 published article · Updated continuously
52 trials tracked for pneumococcal infections: 32 in phase 3 or 4 and 19 with published results. The most-cited published study has 94 citations.
Showing the 50 most-cited and recently-updated of 52 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Prevenar-13 (PCV13) reduced the number of exacerbations, antibiotic use, and hospitalizations in patients with underlying disease (p<0.05) 1. In a large phase 4 trial, PCV13 significantly reduced first episodes of vaccine-type community-acquired pneumonia (VT-CAP) (p=0.0006), nonbacteremic/noninvasive VT-CAP (p=0.0067), and vaccine-type invasive pneumococcal disease (VT-IPD) (p=0.0005) compared to placebo 2. Prevenar (7-valent) induced robust antibody responses, with geometric mean fold rises (GMFR) above baseline for all 7 serotypes, and antibody concentrations persisted at 12 months 3.
V114, a newer pneumococcal conjugate vaccine, showed comparable safety to Prevnar 13 across multiple phase 3 trials. Solicited injection-site adverse event rates were similar between V114 and Prevnar 13 in most studies, with some trials showing statistically significant differences in specific comparisons (e.g., p=0.043 5, p=0.039 6, p=0.003 15), but overall the evidence is mixed regarding superiority in reactogenicity. Systemic adverse event rates were generally comparable, with no significant differences in most trials (e.g., p=0.888 4, p=0.446 6, p=0.885 7, p=0.229 9, p=0.825 10, p=0.912 19, p=0.205 22). Vaccine-related serious adverse events were rare (0-0.3%) and similar between groups 467910121516192022.
Prevnar 13 was also evaluated in various populations. In one trial, 89.9% of participants reported any adverse event, with 86.4% injection-site and 76.8% systemic 13. Another study in children and adults reported local reactions and systemic events within 7 days post-vaccination 1821. Overall, the established evidence supports the efficacy of PCV13 in reducing pneumococcal disease and the safety of both PCV13 and V114, with no major safety concerns identified.
AI synthesis of 18 cited trials, updated Jul 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
